The Academy for Clinical Debates & Controversies in Medicine

The 2^nd Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) Rio de Janeiro, Brazil, March 22-25, 2012

Home Page

Committees

Scientific Program

Click here

Abstract Submission Deadline:
December 15, 2011

A special emphasis will be given to Abstracts during the 2nd Latin America CODHy Congress

Submit your Abstract!

CLICK HERE

codhyLA@codhy.com | www.codhy.com/LA

Preliminary Scientific Program

Friday, March 23, 2012

Hall A

09:00-10:30

Plenary Session 1

Insulin resistance: A multifaceted disease responsible for ASCVD and cancer

Diabetes, obesity and cancer

Diabetes therapy and cancer

Overview of diabetes in Latin America

10:30-11:00

Coffee Break

Hall A

Hall B

Hall C

11:00-12:30

Session 2
Prevention and Early Therapy
Prediabetes therapy: Lifestyle/Drugs
First line therapy in T2D: Combination therapy/Monotherapy

Session 5
Hypertension Controversies

Should we change the target blood pressure in diabetic patients?
Yes/No
Should we avoid antihypertensive drugs that increase glucose/ obesity?
Yes/No

Session 8
Obesity
Do we need anti-obesity drugs or lifestyle intervention only?
Anti-obesity drugs/
Lifestyle intervention
Bio Markers in diabetes and obesity

12:30-13:30

Lunch Break

13:30-15:00

Session 3
Utilization of Insulin Therapy by GPs

Are all sulfonylurea (Su) even?
Yes/No

Starting insulin therapy by GP: BASAL vs. Premix
Basal/Premix

Insulin intensification by GP
Yes/No

Session 6
RAAS in Diabetes

Is intracellular RAAS blockade a therapeutic target?

ACEs, ARBs or DRI: what is the best choice?
Combination RAAS blockade

Session 9
Insulin Resistance/Beta Cell Role in Diabetes Progression
Tools to assess insulin resistance and Beta Cell function
Beta function: Evaluation and clinical applications
Insulin secretion and Insulin resistance: A dynamic interaction

15:00-16:00

Session 4
Treating Hyperlipedia in T2D
Pharmacotherapy for HDL
Pro/Con
Intolerance to statin/ target HDL
Yes/No

Session 7
Meet the Professor
Metabolic Syndrome: Do we need this definition?
Testosterone for the management of Metabolic Syndrome
NASH and the Metabolic Syndrome

Session 10
New Insights to Neuropathy in T2D

Peripheral Neuropathy and small fibers: Diagnosis and therapeutic approach

CAN: A tool to assess the diagnosis by the diabetologist

The brain: New insights with diabetes, Alzheimer and depression

16:00-16:30

Coffee Break

16:30-17:30

Guided Poster Tour # 1

Saturday, March 24, 2012

Hall A

Hall B

Hall C

09:00-10:30

Session 11
Type 2 Diabetes (T2D)

Can we stop Beta Cell destruction?
Yes/No

Early insulin therapy
Yes/No

Session 15
Hypertension Therapy in T2D

Diabetes and resistant hypertension
Managing combination antihypertensive therapy
What is the fourth drug?
New strategies: Baroreceptor devices and renal denervation

Session 19
Glucose Therapy

Should we aim at normal glycaemia or an individual approach?
Normal glycaemia/
Individual approach

Different goals with different therapies

Applications of the ORIGIN study

10:30-11:00

Coffee Break

11:00-12:30

Session 12
Targeting the Kidney

The kidney and its role in Glucose Homeostasis

Glucosuria as a novel approach in diabetes management

SGLT2 Safety barriers

Session 16
Hypoglycaemia

Good or Bad?
Good/Bad
Similar importance in every patient?
Yes/No
Can it be prevented?
Yes/No

Session 20

Interrelationship Between CVD and Diabetes: Focusing on the Incretin System

The rationale for early and aggressive treatment of CVD risk factors in T2DM

Potential CVD effects of incretin-based therapies

12:30-13:30

Lunch Break

13:30-15:00

Session 13
Diagnosis of T2D in Latin America

Prevention and control of Gestational Diabetes in Barranquilla: The Vida Nueva project

Trends and prevalence of T2D in Argentina

New diagnostic non-invasive methods in diabetes screening for Latin America (risk scores and EZScan validation in Latin America)

A1C as diagnostic criteria for diabetes in low- and middle-income settings: Evidence from Peru

Session 17
New Data on Glycaemic Effects of Incretin Based Therapy in T2D

The vascular system and heart

The brain

The liver

Session 21
Bariatric Surgery

Minimal requirements to perform bariatric surgery
Do we have long term data to support efficacy and safety?
Yes/No
Surgery in mild obesity and T2D
1st line/ 2nd line

15:00-16:00

Session 14
Meet the Professor

Omega 3 for every diabetic patient
Pro/Con
Vitamin deficiency in diabetes
Yes/No

Session 18
Regulatory Perspective: Global vs. Country Specific Drug Development

US FDA perspective
China SFDA
Brazil ANVISA
Pharmaceutical perspective

Session 22
Meet the Professor
Glycaemic variability is it important

16:00-16:30

Coffee Break

16:30-17:30

Guided Poster Tour # 2

Sunday, March 25, 2012

Hall A

09:00-10:30

Pleanery Session 23
Impact of Pregnancy Hyperglycemia on Future Cardiovascular Risk Factors

Introduction: GDM definition-implications
Obesity, hypertension and pregnancy
Pharmacological therapy in pregnancy hyperglycemia
Pro/Con
Oral hypoglycemic agents
Insulin
Maternal hyperglycemia: future impact on mothers and children
Discussion

10:30-11:00

Coffee Break

11:00-12:30

Plenary Session 24
Global Breakthroughs in the World of Diabetes

Diabetic drug interaction

GLP1, short/ long term safety

Future therapy for obesity and diabetes: Long acting GLP1/ Insulin

Stem Cell therapy: State of the art

codhyLA@codhy.com | www.codhy.com/LA

	info@comtecmed.com	www.comtecmed.com
Headquarters & Administration: 53 Rothschild Boulevard, PO Box 68, Tel Aviv, 61000,Israel Tel: +972-3-566-6166 Fax: +972-3-566-6177 Email: codhyLA@codhy.com	Comtec Spain Bailen, 95 - 97, pral,1.a - 08009 Barcelona, Spain Tel: +34-93-208-1145 Fax: +34-93-457-9291 Email: spain@comtecmed.com	Comtec China Shanghai 200031, China Tel: +86-21-5466-0460 Direct Line: +86-21-5466-0451 Fax: +86-21-5466-0450 Email: china@comtecmed.com

If you do not want to receive this information in the future, please click to unsubscribe